Anagenesis Biotechnologies

Anagenesis Biotechnologies is a biotechnology startup based in France, founded in 2001. The company focuses on developing regenerative medicines for genetic and age-related muscle degenerative diseases. Anagenesis utilizes preclinical-stage stem cell-based technologies to address the unmet medical needs in treating diseases where specific tissues are lost or damaged, which currently lack effective drugs or transplantable cells. The company's patented technologies, licensed-in from the French national biomedical research agency INSERM, have enabled the generation of natural embryonic precursors of skeletal muscle and the development of protocols for turning these precursors into contractile muscle fibers. This breakthrough has resulted in the production of purer and more abundant muscle cells, which have shown success in colonizing damaged muscles when transplanted in vivo. Anagenesis aims to generate revenue through two main activities: cell therapy for genetic muscle disorders and cell-based screening of small molecules. The company has already secured its first private funding from the AFM (French muscular dystrophy association) to develop applications in the therapeutic area of skeletal muscle. With its innovative approach and exclusive rights to key patents, Anagenesis is poised to make significant strides in advancing regenerative medicine for muscle-related diseases.